Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer

BJU International

Volumn 108, Issue 11, 2011, Pages 1776-1781

  Boutier, Romain ^a,b,c   Girouin, Nicolas ^a,b,c   Cheikh, Alexandre Ben ^a,b,c   Belot, Aurélien ^c,d,e   Rabilloud, Muriel ^c,d   Gelet, Albert ^a,f   Chapelon, Jean Yves ^f   Rouviãre, Olivier ^a,b,c,f  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e INSTITUT DE VEILLE SANITAIRE   (France)

^f INSERM   (France)

Author keywords

cancer recurrence; HIFU; prostate apex; prostate cancer

Indexed keywords

AGED; ARTICLE; CANCER LOCALIZATION; COHORT ANALYSIS; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS;

AGED; BIOPSY; HUMANS; MALE; NEOPLASM, RESIDUAL; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 81255171310     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10251.x     Document Type: Article

References (33)

1. Poissonnier L, Chapelon JY, Rouviere O, et al,. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007; 51: 381-7 (Pubitemid 44937777)
2. Uchida T, Ohkusa H, Yamashita H, et al,. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006; 13: 228-33
3. Blana A, Rogenhofer S, Ganzer R, et al,. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 2008; 72: 1329-33
4. Blana A, Murat FJ, Walter B, et al,. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008; 53: 1194-201
5. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM,. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001; 40: 124-9 (Pubitemid 32786096)
6. Rouviere O, Lyonnet D, Raudrant A, et al,. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001; 40: 265-74 (Pubitemid 34701896)
7. Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C,. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008; 246: 833-44
8. Beerlage HP, van Leenders GJ, Oosterhof GO, et al,. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 1999; 39: 41-6 (Pubitemid 29143108)
9. Blana A, Walter B, Rogenhofer S, Wieland WF,. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004; 63: 297-300 (Pubitemid 38234422)
10. Rouviere O, Mege-Lechevallier F, Chapelon JY, et al,. Evaluation of color Doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 2006; 50: 490-7 (Pubitemid 44189043)
11. Chaussy C, Thuroff S,. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 2001; 15: 437-40 (Pubitemid 32467092)
12. Thuroff S, Chaussy C, Vallancien G, et al,. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003; 17: 673-7 (Pubitemid 37362918)
13. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A,. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006; 97: 56-61
14. Murat FJ, Poissonnier L, Chapelon JY, Colombel M, Rouviere O, Gelet A,. Oncological benefits of a second HIFU session when residual prostate cancer is found following the first HIFU treatment. J Urol 2008; 179: S398
15. Rouviere O, Curiel L, Chapelon JY, et al,. Can color Doppler predict the uniformity of HIFU-induced prostate tissue destruction? Prostate 2004; 60: 289-97 (Pubitemid 39050647)
16. Wiart M, Curiel L, Gelet A, Lyonnet D, Chapelon JY, Rouviere O,. Influence of perfusion on high-intensity focused ultrasound prostate ablation: a first-pass MRI study. Magn Reson Med 2007; 58: 119-27 (Pubitemid 47229924)
17. Futterer JJ, Heijmink SW, Scheenen TW, et al,. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-58 (Pubitemid 44632891)
18. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al,. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17: 1498-509 (Pubitemid 46767598)
19. Kim JK, Hong SS, Choi YJ, et al,. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005; 22: 639-46 (Pubitemid 41572716)
20. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L,. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176: 2432-7 (Pubitemid 44665992)
21. Lim HK, Kim JK, Kim KA, Cho KS,. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study. Radiology 2009; 250: 145-51
22. Mazaheri Y, Shukla-Dave A, Hricak H, et al,. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008; 246: 480-8
23. Ocak I, Bernardo M, Metzger G, et al,. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 2007; 189: 849-58
24. Cheikh AB, Girouin N, Colombel M, et al,. Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 2009; 19: 770-8
25. Heijmink SW, Futterer JJ, Hambrock T, et al,. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-95 (Pubitemid 46981973)
26. Rouvière O, Glas L, Girouin N, et al,. Transrectal HIFU ablation of prostate cancer: assessment of tissue destruction with contrast-enhanced ultrasound. Radiology 2011; DOI: 10.1016/S1569-9056(09)60927-1
27. Obek C, Louis P, Civantos F, Soloway MS,. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999; 161: 494-8
28. Salomon L, Colombel M, Patard JJ, et al,. Value of ultrasound-guided systematic sextant biopsies in prostate tumor mapping. Eur Urol 1999; 35: 289-93 (Pubitemid 29154833)
29. Wefer AE, Hricak H, Vigneron DB, et al,. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164: 400-4 (Pubitemid 30481935)
30. Delongchamps NB, Haas GP,. Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol 2009; 6: 645-52
31. Ben Cheikh A, Girouin N, Ryon-Taponnier P, et al,. [MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results]. J Radiol 2008; 89: 571-7 (Pubitemid 351821148)
32. Kim CK, Park BK, Lee HM, Kim SS, Kim E,. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 2008; 190: 1180-6 (Pubitemid 351684917)
33. Rouviere O, Girouin N, Glas L, et al,. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 2010; 20: 48-55